Quantitative Analysis of Wild Type and the newly generated CRISPR/Cas9 Hpn-/- mouse mammary gland gene expression analysis

Transforming growth factor beta (TGFbeta) is a multifunctional cytokine with a well-established role in mammary gland development and both oncogenic and tumor-suppressive functions. The extracellular matrix (ECM) indirectly regulates TGFbeta activity by acting as a storage compartment of latent TGFbeta, but how TGFbeta is released from the ECM via proteolytic mechanisms remains largely unknown. In this study, we demonstrate that hepsin, a type II transmembrane protease overexpressed in 70% of breast tumors, promotes canonical TGFbeta signaling through the release of latent TGFbeta from the ECM-storage compartment. Mammary glands in hepsin CRISPR knock-out mice showed reduced TGFbeta signaling and increased epithelial branching, accompanied by increased levels of fibronectin and latent TGFbeta1, while overexpression of hepsin in mammary tumors increased TGFbeta signaling. Cell-free and cell-based experiments showed that hepsin is capable of direct proteolytic cleavage of fibronectin but not latent TGFbeta and, importantly, that the ability of hepsin to activate TGFbeta signaling is dependent on fibronectin. Altogether, this study demonstrates a role for hepsin as a regulator of the TGFbeta pathway in the mammary gland via a novel mechanism involving proteolytic downmodulation of fibronectin. RNA was extracted from 2-6 weeks old wild-type (N=3, refference samples) and Hpn-/- (N=3) virgin female mammary glands and sequenced with Illumina NextSeq500 (Illumina, San Diego, CA, USA) to quantitate transcriptional changes in gene expression. Pathway and statistical enrichment analysis were performed in GSEA 4.0.3 software (Subramanian et al., 2005 PMID: 16199517).